Cardiac hypertrophy and fibrosis

March 26, 2019

A sweet way to stay free of cardiac diseases: Sugar-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Trehalose, an artificial sweetener composed of two glucose molecules, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 26/March/2018, 10.29 pm

A sweet way to stay free of cardiac diseases: Sugar-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: Trehalose, an artificial sweetener composed of two glucose molecules, increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 26/March/2018, 10.29 pm https://genomediscovery.org/wp-content/uploads/2019/03/Trehalose-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Trehalose-promotes-Cardiomyocyte-CM-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.ERBB2_.jpg March 26, 2019 March 26, 2019

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

March 25, 2019

Intracardiac injection of Hydrogen gas protects against cardiac hypertrophy and fibrosis: Intracardiac or subcutaneous injection or inhalation of Hydrogen gas decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 25/March/2019, 8.22 am

Intracardiac injection of Hydrogen gas protects against cardiac hypertrophy and fibrosis: Intracardiac or subcutaneous injection or inhalation of Hydrogen gas decreases MiR-29 expression, activates wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 25/March/2019, 8.22 am https://genomediscovery.org/wp-content/uploads/2019/03/Subcutaneous-or-Intracardial-injection-or-inhalation-of-hydrogen-gas-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29.jpg1_.jpg3_.jpg4_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/Subcutaneous-or-Intracardial-injection-or-inhalation-of-hydrogen-gas-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29.jpg1_.jpg3_.jpg4_.jpg March 25, 2019 March 25, 2019

Introduction: What they say: A recent study from the Institute of Pharmacology and Toxicology, Technical University Munich (TUM), 80802, Munich, Germany; DZHK (German Center for Cardiovascular Research), partner site Munich…

March 24, 2019

Ribonucleic acid-based therapy for cardiac hypertrophy and fibrosis: LncRNA ROR decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 24/March/2019, 4.31 pm

Ribonucleic acid-based therapy for cardiac hypertrophy and fibrosis: LncRNA ROR decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1 and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function, via upregulation of its target gene, 24/March/2019, 4.31 pm https://genomediscovery.org/wp-content/uploads/2019/03/LncRNA-ROR-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/03/LncRNA-ROR-attenuates-pathogenesis-associated-with-cardiac-hypertrophy-and-fibrosis-through-down-regulation-of-MiR29-and-up-regulation-of-GSK3B-ICAT.CTNNBIP1-and-GLIS2.jpg March 24, 2019 March 24, 2019

February 5, 2019

Ribonucleic acid-based therapy for cardiac hypertrophy and fibrosis: lncRNA PCGEM decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 5/January/2019, 10.06 pm

Ribonucleic acid-based therapy for cardiac hypertrophy and fibrosis: lncRNA PCGEM decreases MiR-29 expression, activates Wnt- signaling and its components GSK3B, ICAT/CTNNBIP1, HBP1, and GLIS2, attenuates pathologic hypertrophy, inhibits fibrosis of the heart tissue, and improves cardiac function via upregulation of its target gene, 5/January/2019, 10.06 pm https://genomediscovery.org/wp-content/uploads/2019/02/PCGEM-attenuates-cardic-hypertrphy-and-fibrosis-through-down-regualtion-of-miR-29.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2019/02/PCGEM-attenuates-cardic-hypertrphy-and-fibrosis-through-down-regualtion-of-miR-29.jpg February 5, 2019 February 5, 2019

December 13, 2018

AP-1-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: AP-1 (Activator protein-1) increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 13/December/2018, 11.16 pm

AP-1-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: AP-1 (Activator protein-1) increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 13/December/2018, 11.16 pm https://genomediscovery.org/wp-content/uploads/2018/12/XBP1-promotes-cardiomyocyte-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/12/XBP1-promotes-cardiomyocyte-dedifferentiation-and-proliferation-followed-by-redifferentiation-and-regeneration-through-activation-of-Her2.jpg December 13, 2018 December 13, 2018

November 28, 2018

Molecular therapy for enhanced learning, memory, and cognitive ability: AP-1 (Activator protein-1), comprising c-Jun and c-fos and others, increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 28/November/2018, 1.25 pm

Molecular therapy for enhanced learning, memory, and cognitive ability: AP-1 (Activator protein-1), comprising c-Jun and c-fos and others, increases Tissue inhibitor of metalloproteinases 2 (TIMP2) levels, improves cognition, and decreases age-associated decline in memory and learning, via down-regulation of its target genes, 28/November/2018, 1.25 pm https://genomediscovery.org/wp-content/uploads/2018/11/AP1-promotes-learning-and-memory-thorough-induciton-of-TIMP2.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/11/AP1-promotes-learning-and-memory-thorough-induciton-of-TIMP2.jpg November 28, 2018 November 28, 2018

Introduction: What they say: A study from Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, USA; Paul F. Glenn Center for the Biology of…

AP-1-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: AP-1 (Activator protein-1) increases the expression of ERBB2/Her2 and promotes dedifferentiation of cardiomyocytes, via up-regulation of its target gene, 13/December/2018, 11.16 pm

Popular Post